You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Direct Air Capture by Ion-Exchange Sorbent and Low-Grade Heat
SBC: ADVANCED COOLING TECHNOLOGIES INC Topic: C5422aAnthropogenic CO2 emissions are widely accepted as the primary driver of global climate change, leading to many adverse outcomes for humanity. While CO2 emissions are equally distributed within the atmosphere, the negative impacts of human-induced climate change are not, with marginalized people suffering the worst. While renewable energy technologies can reduce future emissions, large-scale atmos ...
STTR Phase II 2023 Department of Energy -
A Facility Scale Automated Mobility System
SBC: Luci, LLC Topic: C5407hThere is a large, unmet need for an energy-efficient, facility-scale mobility system that addresses the needs of underserved communities, particularly people with reduced mobility (PRM). Mobility services in airports and other large facilities, are failing to meet the needs of PRM due to rapidly scaling demand and fragmented systems that remain heavily reliant on manual labor and unreliable commun ...
STTR Phase II 2023 Department of Energy -
Treatment of Inflammatory Complications of Respiratory Infection
SBC: Respana Therapeutics, Inc Topic: NIAIDAbstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SIRPant Technology for anti-Cancer Immunity
SBC: SIRPANT IMMUNOTHERAPEUTICS INC Topic: 102PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
SBC: Trevarx Biomedical, Inc. Topic: 102ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
AI/ML Data Management Software System for NSRCs
SBC: VISIMO LLC Topic: C5315aC53-15a-271273Research labs are unable to effectively collaborate and fully utilize microscopy data due to data silos, insufficient data interoperability, and a lack of common data management standards. To address this problem, this innovation will increase the impact of scientific datasets by delivering (1) an extensible software system and (2) microscopy tools which support findability, accessib ...
STTR Phase II 2023 Department of Energy -
Magnetic Bearing Supported Impeller for Molten Salt Reactor Pump
SBC: ELECTRON ENERGY CORP Topic: C5239iMolten salt reactors (MSR) use molten salts as both a carrier of dissolved fission materials and coolant. Reliable high temperature impeller type pump is indispensable for the safe operation of future MSR. The mechanical pump is considered to be ideal for pumping high temperature and corrosive molten salts compared to the electromagnetic pump because of its efficiency. However, the mechanical pump ...
STTR Phase II 2022 Department of Energy -
A novel PEDF peptide mimetic for diabetic retinopathy
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract The overall goal of Skyran Biologics is to develop a potent topical therapeutic for diabetic retinopathy (DR), a leading cause of vision loss globally. Our research team identified Pigment Epithelium-Derived Factor (PEDF) and showed it is expressed in the eye and provides significant protection to the injured retina. Since its discovery, we identified a 44-mer N-terminus bioactive region ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HS ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health